Latest Post

December 04, 2020

How to get your biologic approved quickly when you don’t have the resources of big pharma

Biologics is a rapidly growing market, with a robust R&amp;D pipeline bringing innovative therapies to treat patients. Today, there are 4,000 more active biologic programs in the pipeline compared to 2015, with biologics development programs growing 2.5 times faster than small molecules. New entrants into the biologics market are driving this rapid growth. As of 2018, emerging companies represented 84% of all early phase research.<sup>1</sup>&nbsp;Not only is this segment driving R&amp;D growth, but they are having commercial success in bringing their drugs to market. In 2018, 65% of new drugs launched were patented by emerging companies.<sup>1</sup>
Abigail Hisler

Abbey Hisler

Director, Segment Marketing, Biologics


Search the Blog





  • Previous Posts
    Diane and Dan's OnDemand Webinar on USP Elastomer Chapter Revisions

    November 20, 2020

    New USP Chapters <381>, <382>, <1381>, and <1382>

    Daniel Bantz

    Daniel Bantz

    Manager, Scientific Communications, Self Injection Systems

    Diabetes Day

    November 13, 2020

    World Diabetes Day

    Aileen Kinsella

    Aileen Kinsella

    Sr. Director, IV Market & Hospital Channel

    Requirements and Standards icon

    November 11, 2020

    Global Compendial and Standards Requirements for Elastomeric Components

    Bettine Boltres

    Bettine Boltres

    Principal, Scientific Affairs & TCS EU

    Analytical Scientist placing a beaker down

    November 09, 2020

    New Method for Endotoxin Quantification

    Olga Laskina

    Olga Laskina PhD.

    Sr. Technical Account Specialist, TCS NA

    What are the top issues that you are facing CPs Chart

    November 05, 2020

    PDA and West Sponsor Symposium on Combination Products

    Fran DeGrazio

    Fran DeGrazio

    Chief Scientific Officer, Scientific Affairs

    Load more